BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21576008)

  • 1. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
    Kreyenbuhl J; Slade EP; Medoff DR; Brown CH; Ehrenreich B; Afful J; Dixon LB
    Schizophr Res; 2011 Sep; 131(1-3):127-32. PubMed ID: 21576008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
    Moisan J; Grégoire JP
    Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
    BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans Affairs.
    Weiser M; Davis JM; Brown CH; Slade EP; Fang LJ; Medoff DR; Buchanan RW; Levi L; Davidson M; Kreyenbuhl J
    Am J Psychiatry; 2021 Oct; 178(10):932-940. PubMed ID: 34256606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
    Opolka JL; Rascati KL; Brown CM; Gibson PJ
    Psychiatr Serv; 2004 Feb; 55(2):151-6. PubMed ID: 14762239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.
    Cooper D; Moisan J; Gaudet M; Abdous B; Grégoire JP
    Can J Psychiatry; 2005 Dec; 50(14):901-8. PubMed ID: 16494259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
    Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics.
    Stam N; Taipale H; Tanskanen A; Isphording L; Okhuijsen-Pfeifer C; Schuiling-Veninga CCM; Bos JHJ; Bijker BJ; Tiihonen J; Luykx JJ
    Clin Transl Sci; 2020 Nov; 13(6):1170-1177. PubMed ID: 32441836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.
    Bitter I; Katona L; Zámbori J; Takács P; Fehér L; Diels J; Bacskai M; Lang Z; Gyáni G; Czobor P
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1383-90. PubMed ID: 23477752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
    Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
    Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA
    Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.
    Ciudad A; Haro JM; Alonso J; Bousoño M; Suárez D; Novick D; Gilaberte I
    Eur Psychiatry; 2008 Jan; 23(1):1-7. PubMed ID: 18023154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
    Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
    J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study.
    Varimo E; Aronen ET; Mogk H; Rättö H; Saastamoinen LK
    J Child Adolesc Psychopharmacol; 2021 Aug; 31(6):421-429. PubMed ID: 33739863
    [No Abstract]   [Full Text] [Related]  

  • 20. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.